Abstract
The Sleeping Beauty (SB) transposase system for somatic integration offers great potential for in vivo gene therapeutic applications and genome engineering. Until recently, however, efficacy of SB transposase as a gene transfer vector especially in large animals was lacking. Herein, we report about the newest viral vector development for delivery of the SB transposase system into large mammals. Over the past decade various hyperactive versions of SB transposase and advanced adenovirus vectors enabling efficient and safe delivery of transgenes in vivo were developed. Already several years ago it was demonstrated that adenovirus vectors can be used for delivery of the SB transposase system into murine liver. Our newest study showed for the first time that a hyperactive transposase system delivered by high-capacity adenoviral vectors can result in somatic integration of exogenous DNA in canine liver, facilitating stabilized transgene expression and phenotypic correction for up to three years in a canine model of human disease. In this review we discuss safety issues and further improvements of this adenovirus based hybrid vector system for somatic integration. In the future this approach paves new paths towards the possible cure of human genetic diseases and novel strategies for in vivo genome engineering in large mammals.
Keywords: Adenovirus, Sleeping Beauty transposase, hybrid vector, persistence, somatic integration, large animal, canine, in vivo, phenotype, cellular genes
Current Gene Therapy
Title: Development of Adenovirus Hybrid Vectors for Sleeping Beauty Transposition in Large Mammals
Volume: 11 Issue: 5
Author(s): Martin Hausl, Wenli Zhang, Richard Voigtlander, Nadine Muther, Christina Rauschhuber and Anja Ehrhardt
Affiliation:
Keywords: Adenovirus, Sleeping Beauty transposase, hybrid vector, persistence, somatic integration, large animal, canine, in vivo, phenotype, cellular genes
Abstract: The Sleeping Beauty (SB) transposase system for somatic integration offers great potential for in vivo gene therapeutic applications and genome engineering. Until recently, however, efficacy of SB transposase as a gene transfer vector especially in large animals was lacking. Herein, we report about the newest viral vector development for delivery of the SB transposase system into large mammals. Over the past decade various hyperactive versions of SB transposase and advanced adenovirus vectors enabling efficient and safe delivery of transgenes in vivo were developed. Already several years ago it was demonstrated that adenovirus vectors can be used for delivery of the SB transposase system into murine liver. Our newest study showed for the first time that a hyperactive transposase system delivered by high-capacity adenoviral vectors can result in somatic integration of exogenous DNA in canine liver, facilitating stabilized transgene expression and phenotypic correction for up to three years in a canine model of human disease. In this review we discuss safety issues and further improvements of this adenovirus based hybrid vector system for somatic integration. In the future this approach paves new paths towards the possible cure of human genetic diseases and novel strategies for in vivo genome engineering in large mammals.
Export Options
About this article
Cite this article as:
Hausl Martin, Zhang Wenli, Voigtlander Richard, Muther Nadine, Rauschhuber Christina and Ehrhardt Anja, Development of Adenovirus Hybrid Vectors for Sleeping Beauty Transposition in Large Mammals, Current Gene Therapy 2011; 11 (5) . https://dx.doi.org/10.2174/156652311797415890
DOI https://dx.doi.org/10.2174/156652311797415890 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Antioxidant Response Element and Oxidative Stress Modifiers in Airway Diseases
Current Molecular Medicine Clinical Potential of Minocycline for Schizophrenia
CNS & Neurological Disorders - Drug Targets Directing an Appropriate Immune Response: The Role of Defense Collagens and other Soluble Pattern Recognition Molecules
Current Drug Targets MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Evaluation of the QuantiFERON®-TB Gold In-Tube Assay and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in an Iranian Referral Hospital
Infectious Disorders - Drug Targets The Impact of Inflammatory Profile on Selenium Levels in Hemodialysis Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Lung Dendritic Cells: Targets for Therapy in Allergic Disease
Current Molecular Medicine Fibronectin Expression in the Intervertebral Disc of Monkey
Current Stem Cell Research & Therapy Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Systematic Investigation of the Effects of Long-Term Administration of a High-Fat Diet on Drug Transporters in the Mouse Liver, Kidney and Intestine
Current Drug Metabolism The Proteasome in Health and Disease
Current Pharmaceutical Design Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Acknowledgment to Contributors
Recent Patents on Inflammation & Allergy Drug Discovery The CX3C-Chemokine Fractalkine in Kidney Diseases
Mini-Reviews in Medicinal Chemistry Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Does the MK2-dependent Production of TNFα Regulate mGluR-dependent Synaptic Plasticity?
Current Neuropharmacology Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Biphasic Lipid Vesicles (Biphasix™) Enhance the Adjuvanticity of CpG Oligonucleotides Following Systemic and Mucosal Administration
Current Drug Delivery